Navigation Links
PreMD Inc. Completes Secured Debenture Financing
Date:10/8/2008

test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit http://www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions. In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


'/>"/>
SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. PreMD Reports Second Quarter Results
2. PreMD Successfully Completes Project for Health & Beauty Company
3. PreMD Reports Further Positive Meetings with the FDA
4. PreMD Appeals American Stock Exchange Delisting Notification
5. PreMD Reports First Quarter Results
6. PreMD Provides Update on FDA Review
7. PreMD Reports Fiscal 2007 Results
8. PreMD Inc. Completes Debenture Financing
9. PreMD Inc. Signs Agreement with Cosmetics Conglomerate
10. PreMD Inc. Announces Debenture Financing
11. PreMD Initiates FDA Review Process and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... ) that allege the statin drug caused patients to ... the U.S. District Court, District of South Carolina. According ... be convened on March 26, 2015 at 10:00 a.m. ... directed to submit a Joint Status report to the ...
(Date:3/4/2015)... PA (PRWEB) March 04, 2015 Cook ... non-profit organization that teaches healthy cooking to people touched ... AstraZeneca Hope Lodge. The program, run by founder Ann ... Hospitality and Sport Management. The unique partnership will expand ... Ann Ogden founded CFYL in 2007. After going through ...
(Date:3/4/2015)... With the growing influence of movies, television, video games ... young adults, combined with the increasingly frantic lifestyle of modern ... keep up with what kids are into these days. It ... a daily basis. , The same is also true for ... used to discreetly talk about them, are constantly changing. These ...
(Date:3/4/2015)... Starting February 2015, Dr. Joseph King of King ... new location in Surrey. , In addition to providing ... Chu also provide comprehensive ophthalmology services, including cataract surgery. ... Cataract and Laser (FVCL). This state of the art ... and Surgeons of British Columbia. Fraser Valley Cataract and ...
(Date:3/4/2015)... The print component of “Organic Living” is ... with a circulation of approximately 173,000 copies and an ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... of heat-dried microbes that have digested the organic material ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:King LASIK relocates to Surrey, British Columbia 2
... could be a new way to help prevent heart disease. ... high-density lipoprotein levels, also known as good cholesterol. Statins have ... disease. They are commonly used to lower low-density lipoprotein (LDL) ... a low level of good cholesterol. In fact, a low ...
... examine the initial mammogram immediately so any follow-up tests ... Between 5 percent and 11 percent of all screening ... for a follow-up mammogram. Many abnormal mammograms turn out ... a breast cancer diagnosis within one year. Even when ...
... examine whether current procedures to treat sore throats were ... an estimated 6.7 million annual sore throat patients, 70 ... of throat cultures and rapid tests to detect streptococcus ... medical help for their sore throats. ,After sampling ...
... performing CPR on heart attack victims found they regularly ... by American Heart Association CPR standards.While the standards call ... personnel were delivering on average 37 -- essentially causing ... to follow the guidelines, they gave about 22 breaths ...
... show attention deficit/hyperactivity disorder (ADHD) affects up to 12 percent ... that increased attention problems at age 7 among kids was ... and toddlers.The study tracked the number of hours kids watched ... about two hours of television a day. Three-year-olds watched about ...
... fast track to heart disease, say researchers based on recent ... risk can be significantly reduced. ,Researchers used two noninvasive ... that leads to heart attacks and stroke -- in the ... had not yet entered puberty, their test results were similar ...
Cached Medicine News:
(Date:3/4/2015)... China Biologic Products, Inc. (NASDAQ: CBPO, "China ... biopharmaceutical company in China, today announced its financial results ... Fourth Quarter 2014 Financial Highlights ... increased by 36.2%, or 36.8% excluding the impact of ... $42.6 million in the same quarter of 2013. ...
(Date:3/4/2015)... PARK, Calif. , March 4, 2015 ... company in the emerging field of regenerative medicine, today ... Executive Officer, will ring The Opening Bell ® ... March 5, 2015. Asterias began trading as an NYSE ... "New York Stock Exchange is a trusted partner ...
(Date:3/4/2015)... Calif. , March 4, 2015  Nevro Corp. ... that has developed and commercialized an innovative, evidence-based neuromodulation ... that it will release financial results for the fourth ... on Wednesday, March 18, 2015. Company management will host ... (4:30 p.m. Eastern Time) on Wednesday, March 18, 2015. ...
Breaking Medicine Technology:China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
... Incorporated (Nasdaq: VPHM ) today announced data ... esterase inhibitor [human]) at the 2011 American Academy of ... through 22, in San Francisco, CA.   ... esterase inhibitor therapy indicated for routine prophylaxis against angioedema ...
... Mass., March 22, 2011 Pervasis Therapeutics, Inc. ... related to PVS-30200, the company,s investigational cell therapy ... late-breaking oral presentation at the upcoming American Association ... in Orlando, Florida. PVS-30200, which ...
Cached Medicine Technology:Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting 2Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting 3Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting 4Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting 5Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting 6Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting 2Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting 3Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting 4
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 L reference mark make it ideal for low volume pipetting....
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
... its wide orifice tip, the Finntip Wide ... suspensions and macromolecules like genomic DNA. This ... cell fragmentation. It is excellent for use ... model, the inside diameter of the orifice ...
Medicine Products: